What's New in Oral Combination Therapy for Type 2 Diabetes?

Introduction

Patient Characteristics of SGLT2 Inhibitor CVOTs

Published SGLT2 Inhibitor CVOT Study Cohorts

Patient Characteristics of SGLT2 Inhibitor CVOTs

Primary Endpoints of Published SGLT2 Inhibitor CVOTs

Role of SGLT2 Inhibitors in Improvement of Renal Outcomes

ADA 2019 Recommendations for Patients With Established ASCVD, HF, or CKD

Updates to ADA Standards of Medical Care in Diabetes

Baseline Characteristics of Published CVOT Trials for SGLT2 Inhibitors

Pooled Data for the Composite of MACE

Pooled Data for HHF by Presence of ASCVD

Effect of SGLT2 Inhibitor on Specific CV and Renal Outcomes

SGLT2 Inhibitors Provide Marked Benefits to Reduce HF and Progressive Renal Decline

Role of SGLT2 Inhibitors in Cardiorenal Complications of T2D

SGLT2 Inhibitor Combination Therapy

Appropriate Use of SGLT2 Inhibitor Combination Therapy

Barriers to Using Combination Therapy

Future Trials With SGLT2 Inhibitors

VERTIS-CV Trial CV and Renal Efficacy and Safety of Ertugliflozin

SGLT2 Inhibitors as Cardiovascular Drugs

Multispecialty Care of Patients With T2D

Concluding Remarks

Abbreviations

Abbreviations (cont)